GGrantIndex
Sort

30,917 grants matching tumor microenvironment

The Role of CXCL12 Signaling in Obesity-Induced Prostate Cancer Progression

$384,412
John Digiovanni · University Of Texas At Austin · R01 · FY2019 · CA

Functional Dissection of Metabolic-Sensing Proline Hydroxylation Pathways

$384,375
Yue Chen · University Of Minnesota · R35 · FY2023 · GM

Functional Dissection of Metabolic-Sensing Proline Hydroxylation Pathways

$384,375
Yue Chen · University Of Minnesota · R35 · FY2025 · GM

Use of Organotypic and Mammary Gland Models to Investigate the Outcomes of Clonal

$384,355
Joan Siefert Brugge · Whitehead Institute For Biomedical Res · P01 · FY2009 · CA

Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images

$384,355
Srinivas Chakra Chennubhotla · University Of Pittsburgh At Pittsburgh · U01 · FY2016 · CA

The Role of Lung Resident Mesenchymal Stem Cells in Post-Chemotherapy Lung Metastases of Breast Cancer

$384,300
Guangwen Ren · Jackson Laboratory · R37 · FY2021 · CA

Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs

$384,300
Frank J. Slack · Beth Israel Deaconess Medical Center · R01 · FY2021 · CA

The Role of Lung Resident Mesenchymal Stem Cells in Post-Chemotherapy Lung Metastases of Breast Cancer

$384,300
Guangwen Ren · Jackson Laboratory · R37 · FY2022 · CA

High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer

$384,283
Dolores Di Vizio · Cedars-Sinai Medical Center · R01 · FY2018 · CA

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$384,278
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2023 · CA

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$384,278
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2022 · CA

Ovarian Cancer: Mechanisms of Neuroendocrine Regulation

$384,255
Anil K Sood · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · CA

Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity

$384,242
Xiaoliu Zhang · University Of Houston · R01 · FY2025 · CA

Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity

$384,242
Xiaoliu Zhang · University Of Houston · R01 · FY2022 · CA

Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages

$384,229
James Louis Rubenstein · University Of California, San Francisco · R01 · FY2014 · CA

Controlling cancer with aspirin-triggered stimulation of resolution

$384,219
Dipak Panigrahy · Boston Children'S Hospital · R01 · FY2012 · CA

Project 4: Chimeric Antigen Receptor T Cell Therapy for the Treatment of Acute Myeloid Leukemia

$384,163
Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · P50 · FY2021 · CA

Synergy of Radiation and Immunotherapy: New Approaches

$384,156
Yang-Xin Fu · Ut Southwestern Medical Center · R01 · FY2016 · CA

Mechanisms of Synergistic Regulation of Stem/Progenitors

$384,150
Hal E. Broxmeyer · Indiana University Indianapolis · R01 · FY2015 · HL

Nutrient Sensing and Transcriptional Regulation

$384,140
Donald E Ayer · University Of Utah · R01 · FY2022 · CA

Microfluidic 3D Assays for Metastatic Cancer

$384,136
Roger D. Kamm · Massachusetts Institute Of Technology · R33 · FY2013 · CA

RNase H2 is a novel therapeutic target in triple negative breast cancer

$384,115
Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

RNase H2 is a novel therapeutic target in triple negative breast cancer

$384,115
Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

MAIT cells as a therapeutic approach for gastrointestinal cancers

$384,092
Daniel Ted Leung · University Of Utah · R21 · FY2024 · CA

Center for Modeling Tumor Cell Migration Mechanics: Administrative Core

$384,080
David J Odde · University Of Minnesota · U54 · FY2016 · CA